Want to see SE:FLERIE full AI Analyst Report?

InDex Pharmaceuticals Holding AB (FLERIE) Price & Analysis

2 Followers

FLERIE Stock Chart & Stats

kr18.60

-kr0.20(-0.98%)

At close: Jul 28 4:00 PM EDT

kr18.60

-kr0.20(-0.98%)

Day’s Range― - ―

52-Week Rangekr15.60 - kr37.41

Previous CloseN/A

Volume46.31K

Average Volume (3M)30.96K

Market Cap

kr1.47B

Enterprise Valuekr1.53K

Total Cash (Recent Filing)kr305.70M

Total Debt (Recent Filing)kr1.70M

Price to Earnings (P/E)―

Beta0.06

Next Earnings

Oct 15, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-10.56

Shares Outstanding86,697,700

10 Day Avg. Volume23,323

30 Day Avg. Volume30,958

Financial Highlights & Ratios

PEG Ratio-0.02

Price to Book (P/B)0.76

Price to Sales (P/S)290.28

P/FCF Ratio-90.91

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Very Low LeverageThe extremely low debt burden limits refinancing and solvency pressure, preserving financial flexibility while the company advances its development programs. Although the capital base is not currently generating positive returns, minimal leverage reduces the risk that interest obligations constrain future operating and partnering decisions.

Focused Immunology PipelineA concentrated focus on immunology and a defined lead program can direct scarce resources toward a specific therapeutic opportunity rather than dispersing investment across many unrelated assets. Cobitolimod also gives partnering efforts a clear development and regulatory objective over the coming quarters.

Improving Free Cash Flow TrendThe year-over-year improvement in free cash flow indicates some progress in the pace of cash consumption, which could modestly extend financial flexibility if maintained. However, the company still burns cash, so this is a directional improvement rather than evidence of self-funding operations or durable cash generation.

Bears Say

Persistent Large LossesVery large and recurring operating losses show that the current cost base substantially exceeds revenue generation. This weakens earnings quality and means future progress depends on successful clinical development, regulatory execution and partnering rather than on an established profitable operating model.

Volatile And Deteriorating RevenueThe sharp reversal from positive prior-period revenue to negative TTM revenue demonstrates inconsistent top-line generation and weak near-term visibility. Because the company relies on partnering and out-licensing rather than product sales, revenue may remain dependent on successfully progressing assets and securing suitable agreement terms.

Ongoing Cash BurnNegative operating and free cash flow indicate that the business is not currently funding its activities internally. Continued cash burn can require reliance on existing capital or future financing and may constrain development choices, particularly if partnering proceeds or milestones do not arrive as planned.

FLERIE FAQ

What was InDex Pharmaceuticals Holding AB’s price range in the past 12 months?

InDex Pharmaceuticals Holding AB lowest stock price was kr15.60 and its highest was kr37.41 in the past 12 months.

What is InDex Pharmaceuticals Holding AB’s market cap?

InDex Pharmaceuticals Holding AB’s market cap is kr1.47B.

When is InDex Pharmaceuticals Holding AB’s upcoming earnings report date?

InDex Pharmaceuticals Holding AB’s upcoming earnings report date is Oct 15, 2026 which is in 12 days.

How were InDex Pharmaceuticals Holding AB’s earnings last quarter?

InDex Pharmaceuticals Holding AB released its earnings results on Jul 09, 2026. The company reported -kr1.017 earnings per share for the quarter.

Is InDex Pharmaceuticals Holding AB overvalued?

According to Wall Street analysts InDex Pharmaceuticals Holding AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does InDex Pharmaceuticals Holding AB pay dividends?

InDex Pharmaceuticals Holding AB does not currently pay dividends.

What is InDex Pharmaceuticals Holding AB’s EPS estimate?

InDex Pharmaceuticals Holding AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does InDex Pharmaceuticals Holding AB have?

InDex Pharmaceuticals Holding AB has 86,697,700 shares outstanding.

What happened to InDex Pharmaceuticals Holding AB’s price movement after its last earnings report?

InDex Pharmaceuticals Holding AB reported an EPS of -kr1.017 in its last earnings report. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of InDex Pharmaceuticals Holding AB?

Currently, no hedge funds are holding shares in SE:FLERIE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

InDex Pharmaceuticals Holding AB

Flerie AB (publ) functions as a venture capital entity, concentrating its investments on nascent businesses. The firm actively seeks to fund biotechnology and pharmaceutical companies dedicated to advancing drug discovery and development, or producing innovative tools and applications aimed at addressing pressing global health concerns. Geographically, their investment scope includes Europe, the United States, and Israel. Founded in 2011, Flerie AB (publ) is headquartered in Stockholm, Sweden, and also operates a branch office in London, United Kingdom.